|
1) Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-37
|
|
|
|
2) Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005; 23: 9441-2
|
|
|
|
|
3) Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004; 240: 644-57
|
|
|
|
|
|
4) Cassidy J, Cunningham D, Berry SR, et al. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) ＋ bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. J Clin Oncol. 2008; 26: (May 20 suppl; abstr 4022)
|
|
|
|
|
|
5) Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-9
|
|
|
|
|
|
6) Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-17
|
|
|
|
|
|
7) Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27: 663-71
|
|
|
|
|
|
8) Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study). #296 2009 Gastrointestinal Cancers Symposium
|
|
|
|
|
|
9) Bechstein WO, Lang H, Köhne C, et al. Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. 2009 ASCO Annual Meeting Abstract No: 4091. J Clin Oncol. 2009; 27: 15s
|
|
|
|
|
|
10) Van Cutsem E, Lang I, Folprecht G, et al. Plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. ASCO –GI Abstr. #281, 2010
|
|
|
|
|
|
11) Bokemeyer C, Kohne C, Rougier P. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO Abstr. #3506, 2010
|
|
|
|
|
|
12) Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28: 4697-705
|
|
|
|
|
|
13) Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with etastatic colorectal cancer. J Clin Oncol. 2010; 28: 4706-13
|
|
|
|
|
|
14) Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42
|
|
|
|
|
|
15) Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007; 25: 4779-86
|
|
|
|
|
|
16) Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-97
|
|
|
|
|
|
17) Kang Y, Ohtsu A, Van Cutsem E, et al. A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). ASCO Abstr. #LBA4007, 2010
|
|
|
|
|